Rossari Biotech Ltd Financials
Company Logo

Rossari Biotech Ltd Financial Statement

Rossari Biotech Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue337.07
Operating Expense291.72
Net Profit27.42
Net Profit Margin8.13
Earning Per Share4.96
EBIDTA45.70
Effective Tax Rate21.70
Invest in Rossari Biotech Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Rossari Biotech Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual1,202.91
Operating Expenses Annual1,041.66
Operating Profit Annual168.03
Interest Annual9.70
Depreciation21.48
Net Profit Annual99.65
Tax Annual34.49

Rossari Biotech Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning40.50
Cash Flow from Operations73.92
Cash Flow from Investing-69.78
Cash Flow from Financing-22.09
Cash Flow at the End22.55

Rossari Biotech Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)13.97
PBIT Margin (%)11.96
PBT Margin (%)10.73
Net PROFIT Margin (%)8.28
Return On Networth / Equity (%)10.96
Return On Networth /Employed (%)14.71
Return On Assets (%)10.19
Total Debt / Equity (X)0.07
Asset Turnover Ratio (%)1.23

Rossari Biotech Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual167.29
Total Current Assets Annual566.77
Non Current Assets Annual713.19
Total Shareholders Funds Annual960.34
Total Assets Annual1,281.17

Rossari Biotech Ltd Earning Calls

EPS (INR)

Expected

6.39

Reported

6.39

Surprise

0.00%

Jun 2024

EPS beaten by 0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 23, 2024, Rossari Biotech Ltd has a market capitalization of 3,725.79 Cr. Value Research classifies it as a Mid-Cap company.
Yes, Rossari Biotech Ltd is debt-free with a debt-to-equity ratio of 0.07.
In FY 2023 , Rossari Biotech Ltd recorded a total revenue of approximately 1,202.91 Cr marking a significant milestone in the company's financial performance.
Rossari Biotech Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.1% and 0.1% annually, respectively..
Rossari Biotech Ltd's current PE ratio is 37.39.
Rossari Biotech Ltd's ROCE averaged 12.9% from the FY ending March 2022 to 2024, with a median of 13.9%. It peaked at 14.0% in March 2024, reflecting strong capital efficiency over the period..
Rossari Biotech Ltd's latest EBIT is Rs. 143.83 Cr, surpassing the average EBIT of Rs. 117.78 Cr over the 5 years..